Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
about
Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related DiseasesHigher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.Soluble receptor for advanced glycation end products in critically ill patients and its associations with other clinical markers and 28-day mortality.Combination of Medicinal Herbs KIOM-79 Reduces Advanced Glycation End Product Accumulation and the Expression of Inflammatory Factors in the Aorta of Zucker Diabetic Fatty Rats.Association of four genetic polymorphisms of AGER and its circulating forms with coronary artery disease: a meta-analysis.Effect of glycemic control on soluble RAGE and oxidative stress in type 2 diabetic patientsThe Receptor for Advanced Glycation End Products (RAGE) Is Associated with Persistent Atrial FibrillationClinical study of advanced glycation end products in egyptian diabetic obese and non-obese patients.RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.The pathological role of advanced glycation end products-downregulated heat shock protein 60 in islet β-cell hypertrophy and dysfunctionCrosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory.A New Hypothesis for Insulin Resistance in Hypertension Due to Receptor Cleavage.Hypoxia mediated release of endothelial microparticles and increased association of S100A12 with circulating neutrophilsAdvanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.The S100B/RAGE Axis in Alzheimer's Disease.Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats.Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.Circulating soluble advanced glycation end product is inversely associated with the significant risk of developing cancer: evidence from a meta-analysis.Increased Levels of sRAGE in Diabetic CKD-G5D Patients: A Potential Protective Mechanism against AGE-Related Upregulation of Fibroblast Growth Factor 23 and Inflammation.Racial differences in circulating levels of the soluble receptor for advanced glycation endproducts in middle-aged and older adults.Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects.High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV.
P2860
Q26747425-C92AB450-DACF-4FB8-B71D-561BB398C354Q34024272-27C86620-BC6D-4F4C-890D-D31779751312Q34564061-27A33B7A-98C6-4BC7-B556-1D29E6031087Q34591116-DB8FA7CA-663C-4EC1-9577-555EACBAA06AQ34876873-E1CD11A4-5B78-4105-AEAA-FD86D767889CQ34960671-7384E291-532E-4584-8BB8-2869F37FADB6Q36132723-282F712D-9E5B-4744-97B0-B1FFB040AB0EQ36735682-BEF4AC9A-141A-4BAB-B772-ECACAE200966Q37152947-64A95036-AFDA-48F8-9C5E-1BFC532382A6Q37268947-808CF9BB-408F-4D7D-BF35-7CE2F6723E21Q38315999-228CAFBB-071C-40A6-A734-43085945F609Q38936100-A7A4A768-EB44-4B4B-9E9D-B0FF37914AE4Q41343627-B9EA6D3B-4418-49DF-9EB0-CFB9071F3C63Q41919002-5F841C14-4911-46AE-A452-4954EC0F07C4Q42115221-B7CDCCA0-B147-4009-9717-00E03F69D53EQ42151789-BD8131AD-EAD5-4A12-B1DB-C6C482429BF4Q42537047-3C1AF006-E86B-4F66-858D-0B059EA23B53Q42589786-C220908C-546E-44A8-93FF-8813FDEC253DQ43742322-464523A8-55FF-40B3-ACEE-00AFCA0EC47AQ45339625-4D65A1E9-AFFD-4589-803F-F031167ED5E1Q51061874-65925C91-E88E-43F4-88D9-FF24F0E4393AQ51553376-A011B44B-95AC-407D-9996-EB4BE78B6247Q54583647-8B96529E-6153-4139-8423-1BC594A3580A
P2860
Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Serum levels of soluble form o ...... patients with type 2 diabetes.
@en
Serum levels of soluble form of receptor for advanced glycation end products
@nl
type
label
Serum levels of soluble form o ...... patients with type 2 diabetes.
@en
Serum levels of soluble form of receptor for advanced glycation end products
@nl
prefLabel
Serum levels of soluble form o ...... patients with type 2 diabetes.
@en
Serum levels of soluble form of receptor for advanced glycation end products
@nl
P2093
P1476
Serum levels of soluble form o ...... patients with type 2 diabetes.
@en
P2093
Hiroyoshi Inoue
Hisashi Adachi
Kazuo Nakamura
Masayoshi Takeuchi
Sho-ichi Yamagishi
Takanori Matsui
Tsutomu Imaizumi
Yayoi Kurita-Nakamura
P356
10.1016/J.MVR.2007.09.004
P577
2007-10-05T00:00:00Z